1001.1500 1.15 (0.12%)
NSE Apr 13, 2026 15:31 PM
Volume: 265.2K
 

1001.15
0.12%
Sharekhan
Q2FY2021 was a soft quarter for Strides. The results missed estimates. Revenues grew 11% YoY to Rs 793 crore while the adjusted PAT at Rs 44 crore declined by 9%. Strtides expects a marked improvement in its performance in 2HFY2021 as compared...
Geojit BNP Paribas upgraded Strides Pharma Science Ltd. to Buy with a price target of 1119.0 on 27 Mar, 2026.
More from Strides Pharma Science Ltd.
Recommended